Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q1 2026 · 10-Q
Revenue$171.17M$171.17M+0.4% vs Q1 2025 Net Income$6.42M$6.42M−74.6% vs Q1 2025 EPS Diluted$0.14$0.14−72.5% vs Q1 2025 Gross Profit$70,322,000−17.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flow$47,840,000+36.4% Free Cash Flowderived$38,333,000+57.2% Margins · derivedGross margin41.1%−8.9 pt vs Q1 2025
Operating margin8.0%−13.9 pt vs Q1 2025
Net margin3.8%−11.1 pt vs Q1 2025
ended Mar 31, 2026 · filed May 7, 2026 · 37 d after period end